NCT04847518 - Assessment of Efficacy of KAN-JANG® in Mild COVID-19 | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

May 26, 2021

Primary Completion Date

January 31, 2022

Study Completion Date

March 31, 2022

Conditions

Covid19

Interventions

DRUG

Kan Jang capsules

"One capsule contains a fixed combination of proprietary~* Andrographis paniculata Nees. herb, native extract, DER native 4,5-8,0 :1 260 mg (Diterpene lactones andrographolide and 14-deoxy, 11,12- didehydroadnrograholide) 15-20 mg~* Eleutherococcus senticosus (Rupr. et Maxim) Harms, root, native extract DER native 17-30:1 : 11.4 mg and other inactive excipients (Polycristalline cellulose, Magnesium stearate)."

OTHER

Placebo capsules

Inactive excipients

Trial Locations (1)

0141

RECRUITING

The First University Clinic of Tbilisi State Medical University, Tbilisi